ERBB2 and breast cancer: The subsequent FDA-approved ISH assays introduced the dual-color chromogenic visualization that enabled HER2/CEN17 ratio determination by brightfield microscopy (Table 3) with excellent agreement to the comparator assays for HER2 status in breast cancer (55, 56).